RTI Biologics Highlights Biologic Innovations at 2009 Arthroscopy Association of North America (ANNA) Annual Meeting

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Biologics, Inc. (RTI) (Nasdaq:RTIX), the Florida-based processor of sports medicine, orthopedic, dental, surgical specialties and other biologic implants, will attend the Arthroscopy Association of North America (AANA) annual meeting in San Diego, Calif. this week to share highlights of RTI’s latest implants for sports medicine surgeons.

Matrix HD™: Matrix HD is the first sterile room-temperature human dermis graft on the market for soft tissue augmentation. Matrix HD is comprised of connective tissue with three-dimensional intertwined fibers that retain the multidirectional and mechanical properties of native dermis, while providing the basic structure to support the patient’s own tissue regeneration. The acellular human dermis is sterilized through Tutoplast® Tissue Sterilization Process and is offered in multiple sizes to accommodate particular soft tissue defects and surgeon need. Matrix HD is well suited for reconstructive surgical applications and covering for use in treatment of chronic skin wounds. It has been used in the treatment of shoulder capsule reconstruction, patellar tendon repair, triceps repair, wound covering and Achilles tendon repair.

Fresh-stored Osteochondral Allografts: RTI’s introduction of its fresh-stored OC allograft line, Fresh OC and Fresh OC Talus, meets surgeon demand for cartilage repair options. RTI’s fresh-stored OC allografts enable surgeons to resurface hyaline cartilage defects with mature hyaline cartilage and healthy subcondral bone in a single procedure. The grafts are cleansed, processed and preserved in an effort to maintain chondrocyte viability. Like all RTI tissue, extensive donor screening in accordance with FDA and AATB requirements is conducted. AP and Lateral radiographs are used to size-match grafts to awaiting patients; contact RTI customer service to submit radiographs for matching.

BioCleanse® Meniscus: The BioCleanse® meniscus is the first wholly sterilized meniscus allograft on the market, meaning both the bone block and meniscal tissue are sterilized. The BioCleanse meniscus provides a safe alternative to traditional aseptically processed meniscus allografts and sets a standard for safety. In addition, RTI offers a slot technique instrument set that has been designed to assist surgeons with accurate preparation of the bone block.

Xenograft Wedge: RTI’s xenograft wedge functions as a natural biologic scaffold, allowing for complete incorporation over time. It remodels with the patient’s own bone comparably to allograft, and is biomechanically equivalent to allograft. It can be easily customized to shape and size using commonly available instruments. The wedge is sterilized through the BioCleanse Tissue Sterilization Process.

Tissue Sterilization Processes: RTI is committed to providing the safest and highest quality allografts for surgeons and their patients. RTI uses validated, patented sterilization processes that include viral inactivation steps; two such processes include the BioCleanse® and Tutoplast® Tissue Sterilization Processes. These processes have been validated by tissue type to penetrate tissue, inactivate viruses, eliminate a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality. Fresh-stored osteochondral allografts are cleansed, processed and preserved to maintain chondrocyte viability, and therefore are not sterilized through one of these processes.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button